Summary sheet
Financing Chiesi Farmaceutici's late stage clinical R&D programme and regulatory approval for the period 2014-2015 for (i) the development of new treatments for respiratory diseases with a particular focus on Asthma and Chronic Obstructive Pulmonary Disease (COPD) and (ii) Infant Respiratory Distress Syndrome (IRDS).
The project aims at strengthening the promoter’s research efforts in the selected therapeutic areas, mainly asthma and COPD. The project will be mostly carried out in the promoter’s R&D centre in Parma (Italy).
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an EIA under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter’s procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project due diligence.